Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis

被引：7

作者：

Hazra, Aniruddha ^{[1
,2
,5
]}

Landovitz, Raphael J. ^{[3
]}

Marzinke, Mark A. ^{[4
]}

Quinby, Connor ^{[1
]}

Creticos, Catherine ^{[1
]}

机构：

[1] Univ Chicago Med, Howard Brown Hlth, Chicago, IL USA

[2] Univ Chicago Med, Dept Med, Sect Infect Dis & Global Hlth, Chicago, IL USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Clin AIDS Res & Educ, Los Angeles, CA USA

[4] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD USA

[5] 5841 S Maryland Ave, MC5065, Chicago, IL 60637 USA

来源：

AIDS | 2023年 / 37卷 / 11期

关键词：

cabotegravir; HIV prevention; long-acting pre-exposure prophylaxis; pre-exposure prophylaxis; seroconversion; CISGENDER MEN; PREVENTION; WOMEN; SEX;

D O I：

10.1097/QAD.0000000000003644

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Objective:We describe the first case of HIV-1 infection in the setting of long-acting injectable cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis to occur in the real world.Design:Case report.Methods:Electronic medical records were reviewed to assess patient history and CAB-LA administration details. Plasma fourth-generation HIV-1/2 Ag/Ab combination immunoassay and HIV-1 RNA quantitative PCR were performed at each injection visit.Results:We report a 28-year-old sex-diverse person assigned male at birth who acquired HIV-1 infection 91 days after transitioning from tenofovir alafenamideemtricitabine to CAB-LA despite on-time dosing and appropriate laboratory monitoring.Conclusion:This patient's history suggests HIV infection despite on-time and appropriate CAB-LA injections. To our knowledge, this is the first case of CAB-LA pre-exposure prophylaxis failure outside the setting of a clinical trial and highlights diagnostic and management challenges that may occur with such breakthrough infections.

引用

页码：1711 / 1714

页数：4

共 12 条

[1]

[Anonymous], 2018, US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States-2017 Update: a clinical practice guideline

[2] Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report [J].

Cohen, Stephanie E. ;

Sachdev, Darpun ;

Lee, Sulggi A. ;

Scheer, Susan ;

Bacon, Oliver ;

Chen, Miao-Jung ;

Okochi, Hideaki ;

Anderson, Peter L. ;

Kearney, Mary F. ;

Coffey, Susa ;

Scott, Hyman ;

Grant, Robert M. ;

Havlir, Diane ;

Gandhi, Monica .

LANCET HIV, 2019, 6 (01) :E43-E50

[3] Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial [J].

Delany-Moretlwe, Sinead ;

Hughes, James P. ;

Bock, Peter ;

Ouma, Samuel Gurrion ;

Hunidzarira, Portia ;

Kalonji, Dishiki ;

Kayange, Noel ;

Makhema, Joseph ;

Mandima, Patricia ;

Mathew, Carrie ;

Spooner, Elizabeth ;

Mpendo, Juliet ;

Mukwekwerere, Pamela ;

Mgodi, Nyaradzo ;

Ntege, Patricia Nahirya ;

Nair, Gonasagrie ;

Nakabiito, Clemensia ;

Nuwagaba-Biribonwoha, Harriet ;

Panchia, Ravindre ;

Singh, Nishanta ;

Siziba, Bekezela ;

Farrior, Jennifer ;

Rose, Scott ;

Anderson, Peter L. ;

Eshleman, Susan H. ;

Marzinke, Mark A. ;

Hendrix, Craig W. ;

Beigel-Orme, Stephanie ;

Hosek, Sybil ;

Tolley, Elizabeth ;

Sista, Nirupama ;

Adeyeye, Adeola ;

Rooney, James F. ;

Rinehart, Alex ;

Spreen, William R. ;

Smith, Kimberly ;

Hanscom, Brett ;

Cohen, Myron S. ;

Hosseinipour, Mina C. .

LANCET, 2022, 399 (10337) :1779-1789

[4]

Eshleman SH, 2015, 30 C RETR OPP INF CA

[5] HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention [J].

Eshleman, Susan H. ;

Fogel, Jessica M. ;

Halvas, Elias K. ;

Piwowar-Manning, Estelle ;

Marzinke, Mark A. ;

Kofron, Ryan ;

Wang, Zhe ;

Mellors, John ;

McCauley, Marybeth ;

Rinehart, Alex R. ;

St Clair, Marty ;

Adeyeye, Adeola ;

Hinojosa, Juan C. ;

Cabello, Robinson ;

Middelkoop, Keren ;

Hanscom, Brett ;

Cohen, Myron S. ;

Grinsztejn, Beatriz ;

Landovitz, Raphael J. .

JOURNAL OF INFECTIOUS DISEASES, 2022, 226 (12) :2170-2180

[6] Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084 [J].

Eshleman, Susan H. ;

Fogel, Jessica M. ;

Piwowar-Manning, Estelle ;

Chau, Gordon ;

Cummings, Vanessa ;

Agyei, Yaw ;

Richardson, Paul ;

Sullivan, Philip ;

Haines, Casey D. ;

Bushman, Lane R. ;

Petropoulos, Christos ;

Persaud, Deborah ;

Kofron, Ryan ;

Hendrix, Craig W. ;

Anderson, Peter L. ;

Farrior, Jennifer ;

Mellors, John ;

Adeyeye, Adeola ;

Rinehart, Alex ;

St Clair, Marty ;

Ford, Susan ;

Rooney, James F. ;

Mathew, Carrie-Anne ;

Hunidzarira, Portia ;

Spooner, Elizabeth ;

Mpendo, Juliet ;

Nair, Gonasagrie ;

Cohen, Myron S. ;

Hughes, James P. ;

Hosseinipour, Mina ;

Hanscom, Brett ;

Delany-Moretlwe, Sinead ;

Marzinke, Mark A. .

JOURNAL OF INFECTIOUS DISEASES, 2022, 225 (10) :1741-1749

[7] Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women [J].

Landovitz, Raphael J. ;

Donnell, Deborah ;

Clement, Meredith E. ;

Hanscom, Brett ;

Cottle, Leslie ;

Coelho, Lara ;

Cabello, Robinson ;

Chariyalertsak, Suwat ;

Dunne, Eileen F. ;

Frank, Ian ;

Gallardo-Cartagena, Jorge A. ;

Gaur, Aditya H. ;

Gonzales, Pedro ;

Tran, Ha V. ;

Hinojosa, Juan C. ;

Kallas, Esper G. ;

Kelley, Colleen F. ;

Losso, Marcelo H. ;

Madruga, J. Valdez ;

Middelkoop, Keren ;

Phanuphak, Nittaya ;

Santos, Breno ;

Sued, Omar ;

Valencia Huamani, Javier ;

Overton, Edgar T. ;

Swaminathan, Shobha ;

del Rio, Carlos ;

Gulick, Roy M. ;

Richardson, Paul ;

Sullivan, Philip ;

Piwowar-Manning, Estelle ;

Marzinke, Mark ;

Hendrix, Craig ;

Li, Maoji ;

Wang, Zhe ;

Marrazzo, Jeanne ;

Daar, Eric ;

Asmelash, Aida ;

Brown, Todd T. ;

Anderson, Peter ;

Eshleman, Susan H. ;

Bryan, Marcus ;

Blanchette, Cheryl ;

Lucas, Jonathan ;

Psaros, Christina ;

Safren, Steven ;

Sugarman, Jeremy ;

Scott, Hyman ;

Eron, Joseph J. ;

Fields, Sheldon D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07) :595-608

[8] Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial [J].

Landovitz, Raphael J. ;

Li, Sue ;

Grinsztejn, Beatriz ;

Dawood, Halima ;

Liu, Albert Y. ;

Magnus, Manya ;

Hosseinipour, Mina C. ;

Panchia, Ravindre ;

Cottle, Leslie ;

Chau, Gordon ;

Richardson, Paul ;

Marzinke, Mark A. ;

Hendrix, Craig W. ;

Eshleman, Susan H. ;

Zhang, Yinfeng ;

Tolley, Elizabeth ;

Sugarman, Jeremy ;

Kofron, Ryan ;

Adeyeye, Adeola ;

Burns, David ;

Rinehart, Alex R. ;

Margolis, David ;

Spreen, William R. ;

Cohen, Myron S. ;

McCauley, Marybeth ;

Eron, Joseph J. .

PLOS MEDICINE, 2018, 15 (11)

[9] Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083 [J].

Marzinke, Mark A. ;

Grinsztejn, Beatriz ;

Fogel, Jessica M. ;

Piwowar-Manning, Estelle ;

Li, Maoji ;

Weng, Lei ;

McCauley, Marybeth ;

Cummings, Vanessa ;

Ahmed, Shahnaz ;

Haines, Casey D. ;

Bushman, Lane R. ;

Petropoulos, Christos ;

Persaud, Deborah ;

Adeyeye, Adeola ;

Kofron, Ryan ;

Rinehart, Alex ;

St Clair, Marty ;

Rooney, James F. ;

Pryluka, Daniel ;

Coelho, Lara ;

Gaur, Aditya ;

Middelkoop, Keren ;

Phanuphak, Nittaya ;

Cohen, Myron S. ;

Hendrix, Craig W. ;

Anderson, Peter ;

Hanscom, Brett ;

Donnell, Deborah ;

Landovitz, Raphael J. ;

Eshleman, Susan H. .

JOURNAL OF INFECTIOUS DISEASES, 2021, 224 (09) :1581-1592

[10] Trends in HIV Preexposure Prophylaxis Prescribing in the United States, 2012-2018 [J].

MPharm, Hyun Jin Song ;

Squires, Patrick ;

Wilson, Debbie ;

Lo-Ciganic, Wei-Hsuan ;

Cook, Robert L. ;

Park, Haesuk .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (04) :395-397

← 1 2 →